Skip to results

Keyword or reference number

Area of interest

Type

Showing 81 to 90 of 353

Guidance and quality standards awaiting development
TitleType
Donidalorsen for preventing hereditary angioedema attacks in people 12 years and over [ID6457]Technology appraisal guidance
Dorocubicel for treating haematological cancer when a suitable donor is unavailable for an allogeneic haematopoietic stem cell transplant [ID6521]Technology appraisal guidance
Dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [TSID12115]Technology appraisal guidance
Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6311]Technology appraisal guidance
Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA963) [ID6426]Technology appraisal guidance
Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age who had symptoms before 13 years [TSID12046]Technology appraisal guidance
Dulaglutide for treating type 2 diabetes [ID1451]Technology appraisal guidance
Dupilumab for treating bullous pemphigoid [ID6479]Technology appraisal guidance
Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years [ID6492]Technology appraisal guidance
Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma [TSID10736]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All